Respiratory Therapist

Localities asked to take tough action against blue ear disease (Nhân Dân): May 05, 2008 at 05:55 AM; Nhan Dan - Localities have been asked to take tough action against blue ear disease (or porcine reproductive and respiratory syndrome - PRRS).

GE Healthcare Signs Global Molecular Diagnostic Agreement to Advance Respiratory Drug Development (Centre Daily Times): May 05, 2008 at 11:11 AM; GE Healthcare, a subsidiary of the General Electric Company (NYSE:GE) announced today that it has signed a non-exclusive agreement with Merck & Co., Inc. to share technology on imaging of the lungs that may help to advance respiratory treatment development. Under terms of the agreement, Merck will be granted access to Spin Signal Technology(TM) (SST) utilizing hyperpolarized Xenon 129 gas, a ...

GE Healthcare Signs Global Molecular Diagnostic Agreement to Advance Respiratory Drug Development (Business Wire via Yahoo! Finance): May 05, 2008 at 10:38 AM; CHALFONT ST GILES, England----GE Healthcare, a subsidiary of the General Electric Company announced today that it has signed a non-exclusive agreement with Merck & Co., Inc. to share technology on imaging of the lungs that may help to advance respiratory treatment development.

Phase 3 data Re: Anti-RSV antibody to be presented at Pediatric Academic Societies Annual Meeting (EurekAlert!): May 05, 2008 at 11:16 AM; HONOLULU, HI, May 4, 2008 – MedImmune today announced that researchers are currently presenting results from a MedImmune-sponsored Phase 3 study involving motavizumab, an investigational monoclonal antibody (MAb) that is being evaluated for its potential to prevent serious disease caused by respiratory syncytial virus (RSV) in high-risk pediatric patients.

Study shows physician judgement important in reducing RSV-related hospitalizations (EurekAlert!): May 05, 2008 at 11:16 AM; HONOLULU, HI, May 5, 2008 – MedImmune announced today that the company presented results from a retrospective chart review that evaluated the use of Synagis® (palivizumab) as a preventive measure against respiratory syncytial virus (RSV) disease in high-risk infants.

News briefs: May issue of the journal Chest (EurekAlert!): May 05, 2008 at 12:22 AM; Previous research has linked the use of long-acting β2-agonists (LABA) to increased risk for adverse events or respiratory-related death in patients with stable, moderate to severe chronic obstructive pulmonary disease (COPD); however, a recent article shows this may not be the case.

Motavizumab Cuts RSV Burden In High-Risk Infants (Medical News Today): May 05, 2008 at 05:12 AM; The investigational second-generation humanized monoclonal antibody motavizumab significantly decreases hospitalizations due to respiratory syncytial virus (RSV) and outpatient acute lower respiratory tract infections (ALRIs) in term American Indian infants at high risk of RSV disease, according to i